DR
DRTSW
Alpha Tau Medical Ltd.
$2.00
+96.08%
$208.6M
No data for this timeframe.
Vol
Market Cap$208.6M
Cap SizeMicro Cap
SEC Reports14
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. L3·CIK 0001871321·Prev Close $1.02
Recent Activity
Jun 3, 2026
SEC
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop and commercialize A
6-K — Impact 7/10
Jun 3, 2026
contract
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urologica
Jun 1, 2026
SEC
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASC
6-K — Impact 7/10
May 18, 2026
SEC
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.7M ($0.12/share) YoY
6-K — Impact 5/10
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
14 SEC filing reports analyzed. Sentiment: 9 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 5.5/10.
BULLISH
6-K
7/10
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop
Jun 3, 2026
BULLISH
6-K
7/10
Alpha Tau announced positive overall survival results from pooled Phase I/II Alpha DaRT pancreatic c
Jun 1, 2026
NEUTRAL
6-K
5/10
Alpha Tau reported Q1 2026 financial results with net loss widening to $22.9M ($0.26/share) from $8.
May 18, 2026
BULLISH
6-K
7/10
Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM
May 11, 2026
BULLISH
6-K
6/10
Alpha Tau announced interim results from its U.S. Alpha DaRT recurrent glioblastoma trial (REGAIN) s
May 11, 2026
NEUTRAL
6-K
3/10
Alpha Tau Medical Ltd. filed a 6-K on May 8, 2026, announcing a conference call to discuss interim c
May 8, 2026
BULLISH
6-K
6/10
Alpha Tau completed enrollment of 88 patients in its U.S. pivotal ReSTART trial for Alpha DaRT in re
May 8, 2026
NEUTRAL
6-K
3/10
Alpha Tau announced the first patient treated in Italy with its Alpha DaRT therapy for pancreatic ca
May 7, 2026
NEUTRAL
6-K
3/10
Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for el
May 5, 2026
BULLISH
6-K
7/10
Alpha Tau announced positive clinical trial results for its Alpha DaRT therapy in pancreatic cancer,
May 4, 2026
NEUTRAL
EFFECT
2/10
Alpha Tau Medical Ltd. received SEC effectiveness for its shelf registration (Form F-3) on May 1, 20
May 4, 2026
BULLISH
6-K
7/10
Alpha Tau Medical announced that a pooled analysis of safety and efficacy data from 58 patients acro
Apr 27, 2026
BULLISH
6-K
7/10
Alpha Tau Medical announced two clinical trial advancements: the first patient treated in Europe und
Apr 23, 2026
BULLISH
6-K
7/10
Alpha Tau Medical announced that clinical data from its Alpha DaRT therapy for pancreatic cancer has
Mar 31, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 658.1% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 3, 2026
contract
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
May 18, 2026
earnings
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026
other
Alpha Tau to Participate in May Investor Conferences
Alpha Tau to Participate in May Investor Conferences 2026
May 11, 2026
fda
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
<p align="center"><em>- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total dis
May 8, 2026
routine
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
May 8, 2026
fda
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to ReSTART
May 5, 2026
fda
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha D
May 4, 2026
fda
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 202
Apr 27, 2026
earnings
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Alpha Tau Announces New Pancreatic Cancer Data at ASCO 2026, Showcasing Combined Results from Three Alpha DaRT® Pancreatic Cancer Studies
Apr 23, 2026
fda
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Ab
Apr 23, 2026
other
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
<p>JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=fjzjfILlRnxPCV_VzbR5SOjzAFQdkXCTjQREyLsCpOzSilt
Mar 31, 2026
other
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
<p align="left">JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=uo1-nlaQihuNkOmg2VvEOCEywacVu69z3J
Mar 16, 2026
other
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference March 2026
Mar 9, 2026
earnings
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval